Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H8X9
UPID:
ZDH11_HUMAN
Alternative names:
Zinc finger DHHC domain-containing protein 11; Zinc finger protein 399
Alternative UPACC:
Q9H8X9; Q6UWR9
Background:
Palmitoyltransferase ZDHHC11, also known as Zinc finger DHHC domain-containing protein 11 or Zinc finger protein 399, plays a crucial role in cellular processes. It localizes in the endoplasmic reticulum, catalyzing the addition of palmitate onto various protein substrates. This enzyme's activity towards NCDN is significant for regulating its association with endosome membranes, impacting cell proliferation and DNA virus-triggered immune responses.
Therapeutic significance:
Understanding the role of Palmitoyltransferase ZDHHC11 could open doors to potential therapeutic strategies. Its involvement in cell proliferation and innate immune responses highlights its potential as a target in developing treatments for diseases where these processes are dysregulated.